Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution

K. Svobodova, H. Lhotska, L. Hodanova, L. Pavlistova, D. Vesela, M. Belickova, J. Vesela, J. Brezinova, I. Sarova, S. Izakova, L. Lizcova, M. Siskova, A. Jonasova, J. Cermak, K. Michalova, Z. Zemanova

. 2020 ; 59 (7) : 396-405. [pub] 20200325

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012420

The karyotype of bone-marrow cells at the time of diagnosis is one of the most important prognostic factors in patients with myelodysplastic syndromes (MDS). In some cases, the acquisition of additional genetic aberrations (clonal evolution [CE]) associated with clinical progression may occur during the disease. We analyzed a cohort of 469 MDS patients using a combination of molecular cytogenomic methods to identify cryptic aberrations and to assess their potential role in CE. We confirmed CE in 36 (8%) patients. The analysis of bone-marrow samples with a combination of cytogenomic methods at diagnosis and after CE identified 214 chromosomal aberrations. The early genetic changes in the diagnostic samples were frequently MDS specific (17 MDS-specific/57 early changes). Most progression-related aberrations identified after CE were not MDS specific (131 non-MDS-specific/155 progression-related changes). Copy number neutral loss of heterozygosity (CN-LOH) was detected in 19% of patients. MDS-specific CN-LOH (4q, 17p) was identified in three patients, and probably pathogenic homozygous mutations were found in TET2 (4q24) and TP53 (17p13.1) genes. We observed a statistically significant difference in overall survival (OS) between the groups of patients divided according to their diagnostic cytogenomic findings, with worse OS in the group with complex karyotypes (P = .021). A combination of cytogenomic methods allowed us to detect many cryptic genomic changes and identify genes and genomic regions that may represent therapeutic targets in patients with progressive MDS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012420
003      
CZ-PrNML
005      
20220906104956.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/gcc.22841 $2 doi
035    __
$a (PubMed)32170980
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Svobodová, Karla, $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $d 1986- $7 xx0276416
245    10
$a Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution / $c K. Svobodova, H. Lhotska, L. Hodanova, L. Pavlistova, D. Vesela, M. Belickova, J. Vesela, J. Brezinova, I. Sarova, S. Izakova, L. Lizcova, M. Siskova, A. Jonasova, J. Cermak, K. Michalova, Z. Zemanova
520    9_
$a The karyotype of bone-marrow cells at the time of diagnosis is one of the most important prognostic factors in patients with myelodysplastic syndromes (MDS). In some cases, the acquisition of additional genetic aberrations (clonal evolution [CE]) associated with clinical progression may occur during the disease. We analyzed a cohort of 469 MDS patients using a combination of molecular cytogenomic methods to identify cryptic aberrations and to assess their potential role in CE. We confirmed CE in 36 (8%) patients. The analysis of bone-marrow samples with a combination of cytogenomic methods at diagnosis and after CE identified 214 chromosomal aberrations. The early genetic changes in the diagnostic samples were frequently MDS specific (17 MDS-specific/57 early changes). Most progression-related aberrations identified after CE were not MDS specific (131 non-MDS-specific/155 progression-related changes). Copy number neutral loss of heterozygosity (CN-LOH) was detected in 19% of patients. MDS-specific CN-LOH (4q, 17p) was identified in three patients, and probably pathogenic homozygous mutations were found in TET2 (4q24) and TP53 (17p13.1) genes. We observed a statistically significant difference in overall survival (OS) between the groups of patients divided according to their diagnostic cytogenomic findings, with worse OS in the group with complex karyotypes (P = .021). A combination of cytogenomic methods allowed us to detect many cryptic genomic changes and identify genes and genomic regions that may represent therapeutic targets in patients with progressive MDS.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a chromozomální aberace $7 D002869
650    12
$a klonální evoluce $7 D060965
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ztráta heterozygozity $7 D019656
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a myelodysplastické syndromy $x klasifikace $x genetika $x patologie $7 D009190
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    _2
$a analýza přežití $7 D016019
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lhotská, Halka $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0276414
700    1_
$a Hodaňová, Lucie $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0276423
700    1_
$a Pavlistova, Lenka $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Vidláková, Denisa $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $7 xx0276420
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Brezinova, Jana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Sarova, Iveta $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Izakova, Silvia $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Lizcova, Libuse $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Siskova, Magda $u First Medical Department, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Jonasova, Anna $u First Medical Department, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Michalova, Kyra $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $u First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
773    0_
$w MED00001898 $t Genes, chromosomes & cancer $x 1098-2264 $g Roč. 59, č. 7 (2020), s. 396-405
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32170980 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20220906104952 $b ABA008
999    __
$a ok $b bmc $g 1650733 $s 1132799
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 59 $c 7 $d 396-405 $e 20200325 $i 1098-2264 $m Genes, chromosomes & cancer $n Genes Chromosom Cancer $x MED00001898
LZP    __
$a Pubmed-20210420
Back

Find record

Citation metrics

Archiving options